Line Probe Assay, The Best Molecular Diagnostic Tool and Improve the Multi Drug Resistance Detection in Pulmonary and Extra Pulmonary Tuberculosis Cases in Balochistan
PDF

Keywords

Multi Drug Resistance
Line probe assay
pulmonary tuberculosis
extra pulmonary tuberculosis
cases in Balochistan

How to Cite

Muhammad Saleem, Syed Muhammad Ishaque, Muhammad Shafee Khosa, Zia Ud Din, Nargis Haider Kakar, Abdul Rauf, Muhammad Ali Khan, Asma Zafar, & Irfana Iqbal. (2020). Line Probe Assay, The Best Molecular Diagnostic Tool and Improve the Multi Drug Resistance Detection in Pulmonary and Extra Pulmonary Tuberculosis Cases in Balochistan. Pak-Euro Journal of Medical and Life Sciences, 3(3), 97-104. https://doi.org/10.31580/pjmls.v3i3.1545

Abstract

Introduction:

Mycobacterium tuberculosis (MTB) appears resistant to first line antibiotics e.g. rifampicin and isoniazid is said to be Multi-drug resistant Tuberculosis(MDR-TB), Globally 15.3 million cases emerge where as in Pakistan 1.8 million cases reported included Pakistan in 22 high burden cases. For MDR-TB detection in this study LPA a molecular technique was used.

Methods: A number 400 patients were studied in this study after sample collection in open space for pulmonary sample and for extra pulmonary samples were taken in sterile syringe or containers auramine staining was performed and examine under 40X lenes, DNA Extinction ; the DNA was extracted by Genolyse Method, Master Mix preparation: The master mix was adjusted by mixing of master mix A and mix B for further uses. e.g. Amplification and hybridization: for amplification process thermocycler was used as PCR amplification and for hybridization the PCR products were analyzed  to the strips on which probe are presents and interpreted

Results: The study was conducted among different ethnic groups and both male & female genders of Balochistan. Overall 400 smear negative and positive samples from TB DOTS and PMDTS were applied on LPA for the diagnosis of Mono and MDR-TB. In total 400 cases, 236 (59%) were MTB positive, 162 (40%) were found MTB negative and 2 were detected as invalid. In this study also analysis were based on gender(male and Female), ethnicity (Pashtoon, Baloch, Hazara and Sattler’s )and site (DOTS and PMDTS).

Conclusion: in conclusion MDR-TB detection by LPA is more sensitive technique to others and prevalence rate of MDR-TB in enrolled patients at PMDTS and DOTS program at alarming stage, a serious threats  to public. to overcome this issue molecular LPA is must for the MTB diagnosis on routine bases and to make possible reduction of MDR-TB cases. The outcomes of this study enhance about the mutation occurs in MTB is highly which promote TB in MDR-TB and in future MDR-TB in to XDR-TB. It is highly suggested for the development in the diagnostic techniques and tools .i.e.LPA  for MDR-TB detection.

https://doi.org/10.31580/pjmls.v3i3.1545
PDF

References

1. World Health Organization. WHO Report 2017 Global Tuberculosis Control.Geneva: WHO. (Online). (Cited 2017).
Available from URL:http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809_eng.pdf

2. Javaid A, Hasan R, Zafar A, Ghafoor A, Pathan A, Rab A, et al. Prevalence ofprimary multidrug resistance to anti-tuberculosis drugs in Pakistan. Int JTuberculosis and Lung Dis 2008; 12: 326-31.
3.. Nsofor CA, Jiang Q, Wu J, Gan M, Liu Q, Zuo T, et al. Transmission is a noticeable cause of resistance among treated tuberculosis patients in Shanghai. China Sci Rep. 2017;7:7691.
4 . Dobler CC, Korver S, Batbayar O, Nyamdulam B, Oyuntsetseg S, Tsolmon B, et al. Multidrug-resistant tuberculosis in patients for whom first-line treatment failed, Mongolia, 2010–2011. Emerg Infect Dis. 2015;21:1451–4
5. World Health Organization (2009) Global tuberculosis control 2009. Geneva, Switzerland: World Health Organization Press.
6. Warren RM, Streicher EM, van Pittius NCG, Marais BJ, van der Spuy GD, et al. (2009) The clinical relevance of mycobacterial pharmacogenetics. Tuberculosis 89 (3): 199–202.
7. World Health Organization (2010) Global tuberculosis control 2010. Geneva, Switzerland: World Health Organization Press.
8. World Health Organization. Molecular line probe assays for the rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement. WHO, Geneva, Switzerland. 2008; http://www.who.int/tb/laboratory/lpa_policy.pdf
9. Ali A, Hasan Z, Moatter T, Tanveer M, Hasan R. M. tuberculosis Central Asian Strain 1 MDR isolates have more mutations in rpoB and katG genes compared with other genotypes. Scand J Infect Dis 2009; 41: 37-44.
10. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32: 1165-74.
11. Yadav R N, Singh B K, Sharma S K, Sharma R, Soneja M, Sreenivas V, et al. Comparative Evaluation of GenoTypeMTBDRplus Line Probe Assay with Solid Culture Method in Early Diagnosis of Multidrug Resistant Tuberculosis (MDR-TB) at a Tertiary Care Centre in India. PLoS ONE 2013; 8(9): e72036. https://doi.org/10.1371/journal.pone.0072036 PMID: 24039735
12. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the GenoType MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 2005; 43:3699–3703. PMID: 16081898
13. Buyankhishig B, Oyuntuya T, Tserelmaa B, Sarantuya J, Lucero M G, Mitarai S. Rapid molecular testing for multi-resistant tuberculosis in mongoliya: A diagnostic accuracy study. Int J Mycobacteriol. 2012; 40–44. https://doi.org/10.1016/j.ijmyco.2012.01.007 PMID: 26786948
14. Noor R, Akhter S, Rahman F, Munshi SK, Kamal SMM, et al. (2013) Frequency of extensively drug resistant tuberculosis (XDR-TB) among retreatment cases in NIDCH, Dhaka, Bangladesh. J Infect Chemother 19 (2): 243– 248.
15. Islam S, Rahman F, Munshi SK, Ahmed J, Kamal SMM, et al. (2012) Use of fluorescein diacetate staining to detect viable Mycobacterium tuberculosis. Bang J Med Sci 11 (4): 322–330.
16. Munshi SK, Rahman F, Kamal SMM, Noor R (2012) Comparison among different diagnostic methods used for the detection of extra-pulmonary tuberculosis in Bangladesh. Int J Mycobacteriol 1: 190–195.
17. Barnard M, van Pittius NCG, van Helden PD, Bosman M, Coetzee G, et al. (2012) The diagnostic performance of the GenoTypeMTBDRplus Version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. J Clin Microbiol 50 (11): 3712–3716.
18. Barnard M, Parsons L, Miotto P, Cirillo D, Feldmann K, et al. (2010) Laboratory manual for molecular detection of drug-resistant tuberculosis by line probe assay. Geneva, Switzerland: FIND19. Kim BJ, Lee SH, Lyu MA, Kim SJ, Bai GH, et al. (1999) Identification of mycobacterial species by comparative sequence analysis of the RNA polymerase gene (rpoB). J Clin Microbiol 20: 1714–1720. 34. Piatek AS, Telenti A, Murray MR, El-Hajj H, Jacobs WR, et al. (2000) Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 44: 103–110.
21. Hillemann D, Ru¨sch-Gerdes S, Richter E (2007) Evaluation of the Genotype MTBDRplus assay for rifampicin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and in clinical specimens. J Clin Microbiol 45: 2635–2640.
22. Shafee M, Abbas F, Tanveer Z, Whitelaw A, Tow LA, Ashraf M, Ahmad I, Patching SG, Jabbar A, Akbar A, Mustafa MZ. Predominance of Central Asian strain (ST 26) in Mycobacterium tuberculosis isolates from Balochistan by spoligotyping. The Journal of Infection in Developing Countries. 2019 Jul 31;13(07):619-25.
23. Barnard M, Albert H, O’Brien R, Coetzee G, Bosman M (2007) Assessment of the MTBDRPlus assay for the rapid detection of multidrug-resistant tuberculosis from smear-positive sputa. Int J Tuberc Lung Dis 11: S229.
24. Shiferaw G, Woldeamanuel Y, Gebevehu M, Girmachew F, Demessie D, et al. (2007) Evaluation of microscopic observation drug susceptibility assay for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 45 (4): 1093–1097.
25. Khoharo HK, Shaikh IA. Drug resistance patterns in pulmonary tuberculosis.JPMA.2011;61:229-233.
26. Sabouni R, Kourout M, Chaoui I, Jordaan A, Akrim M, et al. (2008) Molecular analysis of multidrug resistant Mycobacterium tuberculosis isolates from Morocco. Annals Microbiol 58: 749–754.
27. Jou R, Chen H, Chiang C, Yu M, Su I (2005) Genetic diversity of multidrugresistant Mycobacterium tuberculosis isolates and identification of 11 novel rpoB alleles in Taiwan. J Clin Microbiol 43: 1390–1394.
28. World Health Organization (2011) Drug Resistant Tuberculosis in the SouthEast Asia region. Geneva, Switzerland: World Health Organization Press.
29. Helb D, Jones M, Story E, Boehme C, Wallace E (2010) Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, nearpatient technology. J Clin Microbiol 48 (1): 229–237.
30. Van Rie A, Warren R, Mshanga I, Jordaan A, van der Spuy GD, et al. (2001) Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J Clin Microbiol 39: 636–641.
31. Kiepiela P, Bishop KS, Smith AN, Roux L, York DF (2000) Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwa- Zulu Natal, South Africa. Tuber Lung Dis 80: 47–56.
32. Baker LV, Brown TJ, Maxwell O, Gibson AL, Fang Z, et al. (2005) Molecular analysis of isoniazid-resistant Mycobacterium tuberculosis isolates from England and Wales reveals the phylogenetic significance of the ahpC-46A polymorphism. Antimicrob Agents Chemother 49: 1455–1464.
33. World Health Organisation. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational ’how to’ practical considerations. WHO, Geneva, Switzerland. 2011; http://whqlibdoc.who. int/publications/2011/9789241501569_eng.pdf Accessed January 13 2012.
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.